Covid vaccine after infection give higher protection against illness, show 2 Lancet studies

New Delhi: Two new studies published in The Lancet have confirmed that COVID-19 vaccination provides additional protection to people who have already been infected with SARS-CoV-2, especially from severe illness.

According to the first study conducted in Brazil, researchers found four vaccines – including Oxford-AstraZeneca (ChAdOx1), which is widely used in India, Covisheeld, CoronaVac, Janssen (Ad26.COV2.S) and Pfizer-BioNTech (BNT162b2) Used as – symptomatic re-infection and provide additional protection against serious consequences such as hospitalization and death in people who have already had SARS-CoV-2 infection.

More than 22,000 participants were included in the study.

agencies

Vaccine effectiveness against symptomatic reinfection was 39% for CoronaVac, 56% for Oxford-AstraZeneca, 44% for Janssen and Pfizer in people who had SARS-CoV-2 infection and were subsequently vaccinated. -BioNtech was 65%. The effectiveness against hospitalization and death was 81% for CoronaVac, 90% for Oxford-AstraZeneca, 58% for Janssen and 90% for Pfizer-BioNtech.

It said that out of 22,566 re-infection cases, 1,545 people were hospitalized and 290 people died within 28 days of testing positive.

Researchers say the study calms the ongoing debate about whether already infected individuals need to be vaccinated.

“All four of these vaccines have proven to provide significant additional protection, reducing hospitalization and death for people with previous COVID-19 infections. Our results suggest that the vaccine benefits far outweigh any potential risks. and supports the case for vaccination, including the complete vaccine series, among individuals with prior infection,” says study author Julio Croda, Universidad Federal de Mato Grosso do Sul and Fundacao.

Originally published at Pen 18